Trial Profile

A Phase I Study of a Personalized NeoAntigen Cancer Vaccine With Radiotherapy Plus Pembrolizumab/MK-3475 Among Newly Diagnosed Glioblastoma Patients

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 May 2024 Planned End Date changed from 1 Jan 2026 to 1 Jun 2026.
24 May 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Jun 2025.
08 Jun 2021 Results (n=5) assessing assess the immunogenicity, safety and early clinical activity of NEO-PV-01 in combination with pembrolizumab for patients with treatment refractory metastatic solid tumors or or vaccine alone as an adjuvant treatment, presented at the 57th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com